Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carbamazepine
Drug ID BADD_D00356
Description Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.[L1335] Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.[A180319]
Indications and Usage Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia.[L1335] In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures.[A180301,L1335] Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder.[L1335] Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.[A180415,A180421]
Marketing Status approved; investigational
ATC Code N03AF01
DrugBank ID DB00564
KEGG ID D00252
MeSH ID D002220
PubChem ID 2554
TTD Drug ID D04MSM
NDC Product Code 62512-0024; 30698-421; 50268-172; 60687-583; 63629-9292; 66993-409; 70518-3266; 70771-1470; 0615-8125; 0781-5987; 0904-6885; 49452-1705; 63552-060; 0078-0510; 0078-0511; 16571-681; 16714-064; 0093-0778; 17856-0029; 29033-019; 30698-419; 35561-355; 50090-0384; 51672-4047; 51672-4151; 54092-173; 60429-934; 60687-594; 63629-8721; 70518-0181; 70771-1469; 70954-240; 71205-025; 75834-220; 12658-0525; 12658-0526; 0904-7116; 42419-014; 35561-357; 51672-4149; 54092-171; 59746-789; 60505-2805; 63629-8743; 66993-407; 67386-621; 68788-7210; 70518-1433; 59746-790; 63629-8753; 68084-562; 68382-557; 70518-3176; 0781-5988; 16714-063; 27241-233; 29033-004; 29300-382; 35561-356; 51407-215; 60505-2807; 70518-1545; 71930-073; 72162-2021; 0781-8016; 0832-6022; 12658-0561; 12658-0565; 48087-0051; 70966-0020; 76003-0251; 13668-268; 0093-0109; 27241-232; 43063-328; 50268-170; 54092-172; 60505-2806; 68788-7825; 70518-1436; 70518-2242; 70518-3335; 71335-0461; 71335-0691; 71930-072; 75834-221; 0904-3854; 51927-2176; 13668-271; 51672-4125; 63629-8715; 68084-444; 68382-555; 70518-1769; 70518-2456; 70518-3699; 70518-3773; 0832-6023; 12658-0452; 51552-0653; 62991-1027; 65344-0028; 65344-0040; 0078-0512; 27241-231; 0121-0947; 43353-953; 59746-791; 70518-2426; 70518-3146; 71930-074; 72189-157; 0904-6172; 12658-0406; 12658-0541; 0078-0509; 0093-0090; 29033-020; 51672-4005; 51672-4123; 55154-1396; 60505-0183; 60687-479; 63629-8720; 68094-007; 68382-556; 70518-2841; 70518-3591; 70518-3694; 71335-1730; 12658-0486; 38779-0114; 48087-0052; 0078-0508; 16714-065; 30698-423; 50268-171; 51672-4150; 58118-0268; 66993-408; 68071-2701; 70518-2489; 70518-3174; 70771-1468; 0615-3505; 72664-218; 0832-6024; 65372-1102; 16571-680; 16571-682; 0121-1894; 50090-5740; 51672-4041; 51672-4124; 60429-032
UNII 33CM23913M
Synonyms Carbamazepine | Carbamazepine Acetate | Carbamazepine Dihydrate | Carbamazepine Hydrochloride | Carbamazepine L-Tartrate (4:1) | Carbamazepine Anhydrous | Carbamazepine Sulfate (2:1) | Carbazepin | Epitol | Finlepsin | Neurotol | Tegretol | Amizepine | Carbamazepine Phosphate
Chemical Information
Molecular Formula C15H12N2O
CAS Registry Number 298-46-4
SMILES C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oromandibular dystonia17.01.03.0060.000279%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000837%Not Available
Intellectual disability17.03.07.001; 19.21.06.0010.000837%Not Available
Hypertransaminasaemia09.01.02.0050.000372%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.0080.000186%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.002790%
Neurological decompensation17.02.05.0300.000465%Not Available
Vulvovaginal erythema23.03.06.017; 21.08.02.0110.000279%Not Available
Hypoxic-ischaemic encephalopathy22.02.02.011; 17.13.02.006; 24.04.06.0210.000186%Not Available
Foetal growth restriction18.03.01.0020.000558%
Sperm concentration decreased13.20.04.008--Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.000372%
Slow speech19.19.02.004; 17.02.08.0160.000186%Not Available
Drug-induced liver injury09.01.07.023; 12.03.01.0440.008834%Not Available
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.027190%Not Available
Language disorder19.19.01.006; 17.02.08.0150.000558%Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.000502%Not Available
Sinus node dysfunction02.03.03.0170.000558%
Irregular breathing22.02.01.0260.000186%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.001116%
Frustration tolerance decreased19.04.02.0160.000186%Not Available
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Somatic symptom disorder19.24.01.0060.000186%Not Available
Anaemia folate deficiency14.12.02.009; 01.03.01.0050.000186%Not Available
B precursor type acute leukaemia16.01.01.004; 01.10.01.0040.000186%Not Available
Coeliac disease14.02.01.007; 10.04.04.012; 07.17.01.0080.000186%Not Available
Concomitant disease aggravated08.01.03.0630.000465%Not Available
Confabulation19.10.03.0090.000186%Not Available
Conjunctival erosion06.06.02.0080.000186%Not Available
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.001023%Not Available
The 28th Page    First    Pre   28 29 30 31 32    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene